|
赵侠 |
|
|
主任药师 |
|
|
研究领域：主要从事临床药理及个体化给药研究 |
|
|
电子邮箱：zxyjk@126.com |
|
|
教育背景 |
|
|
北京大学医学部临床药学硕士（2009） |
|
|
北京医科大学药学学士（1993） |
|
|
工作经历 |
|
|
2011.08至今 北京大学第一医院药学部主任药师 |
|
|
2004.08-2011.08 北京大学第一医院药剂科副主任药师 |
|
|
1998.03-2004.08 北京医科大学第一医院药剂科主管药师 |
|
|
1993.08-1998.03 北京医科大学第一医院药剂科药师 |
|
|
社会兼职 |
|
|
中国药理学会药物临床试验专业委员会常务委员 中国药理学会临床药理专业委员会委员 中国药理学会治疗药物监测研究专业委员会委员 药品监督管理局药品审评中心外聘专家 药品监督管理局审核查验中心GCP检查员 |
|
|
代表性论文 |
|
|
1 Zhao X, Wang Z, Wang Y, Zhang H, Blode H, Yoshikawa K, Becker C, Unger S, Frey R, Cui Y*. Pharmacokinetics of the Soluble Guanylate Cyclase Stimulator Riociguat in Healthy Young Chinese Male Non-Smokers and Smokers: Results of a Randomized, Double-Blind, Placebo-Controlled Study. Clinical Pharmacokinetics. 2016;55(5):615–624. doi:10.1007/s40262-015-0337-4 |
|
|
2 Zhao X, Cui Y*, Zhao S, Lang B, Broedl U, Salsali A, Pinnetti S, Macha S. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus. Clinical Therapeutics. 2015,37(7):1493-1502. doi:10.1016/j.clinthera.2015.05.001 |
|
|
3 Chen S, Ding W, Zhang N, Qian Xiang, Yi-Min Cui, Xia Zhao*. Influence of OATP1B1 and OATP1B3 mutations and glomerular filtration rate on trough serum digoxin concentration in the Chinese population: A prospective cohort study. Medicine, 2019, 98(14): e15088. |
|
|
4 Nan Zhao, Bo Jia, Hong Zhao, Junyu Xu, Xiaoyan Sheng, Lin Luo, Zhangma Huang, Xingan Wang, Qingyun Ren, Yingjun Zhang, Xia Zhao*, Yimin Cui*. A First-in-Human Trial of GLS4, a Novel Inhibitor of Hepatitis B Virus Capsid Assembly, following Single- and Multiple-Ascending-Oral-Dose Studies with or without Ritonavir in Healthy Adult Volunteers. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY. 2020, 64(1): e01689-19. 5Sheng XY, Liang Y, Yang XY, Li-E Li, Xia Ye, Xia Zhao*,Yi-Min Cui*. Safety, pharmacokinetic and pharmacodynamic properties of single ascending dose and continuous infusion of remimazolam besylate in healthy Chinese volunteers. Eur J Clin Pharmacol. 2020;76(3):383–391. |
|
|
6 Xie R#, Zhang Y#, Zhao N, Zhou S, Wang X, Han W, Yu Y, Zhao X*, Cui Y*. Pharmacokinetics and safety of recombinant human interleukin-1 receptor antagonist GR007 in healthy Chinese subjects. European Journal of Drug Metabolism and Pharmacokinetics. 2019;44(3):353–360. doi:10.1007/s13318-018-0523-5 |
|
|
|
|
|
荣誉奖励 |
|
|
1 2013年中华医学会临床药学分会的首届优秀临床药师奖 |
|
|
2 2013年华夏医学科技奖三等奖(第三完成人) |
|
|
3 2012年中国药学会科学技术奖二等奖(第二完成人) |
|